A HER2-specific Modified Fc Fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis

Molecular Therapy

Volumn 23, Issue 11, 2015, Pages 1722-1733

  Leung, Kin Mei ^a   Batey, Sarah ^a   Rowlands, Robert ^a   Isaac, Samine J ^a   Jones, Phil ^a   Drewett, Victoria ^a   Carvalho, Joana ^a   Gaspar, Miguel ^a   Weller, Sarah ^a   Medcalf, Melanie ^a   Wydro, Mateusz M ^a   Pegram, Robert ^a   Mudde, Geert C ^a   Bauer, Anton ^a   Moulder, Kevin ^a   Woisetschläger, Max ^a   Tuna, Mihriban ^a   Haurum, John S ^a   Sun, Haijun ^a  

^a Babraham Research Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FS 102; IMMUNOGLOBULIN FC FRAGMENT; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FS102 ANTIBODY FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; GENE DOSAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; MCF-7 CELL LINE; NEOPLASMS; NUDE MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948711124     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.127     Document Type: Article

References (43)

1. Hynes NE, and Lane HA (2005). ERBB receptors, and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
2. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. (1999). The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96: 4995-5000.
3. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11: 495-505.
4. Graus-Porta D, Beerli RR, Daly JM, and Hynes NE (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655.
5. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, and Carpenter G (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257.
6. Ross JS, and Fletcher JA (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 3: 237-252.
7. Okines AF, and Cunningham D (2010). Trastuzumab in gastric cancer. Eur J Cancer 46: 1949-1959.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse, and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
9. Gravalos C, and Jimeno A (2008). HER2 in gastric cancer: a new prognostic factor, and a novel therapeutic target. Ann Oncol 19: 1523-1529.
10. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al.; EMILIA Study Group. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783-1791.
11. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. (2010). Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites, and antibody properties. Protein Eng Des Sel 23: 289-297.
12. Hasenhindl C, Traxlmayr MW, Wozniak-Knopp G, Jones PC, Stadlmayr G, Rüker F, et al. (2013). Stability assessment on a library scale: a rapid method for the evaluation of the commutability, and insertion of residues in C-Derminal loops of the CH3 domains of IgG1-Fc. Protein Eng Des Sel 26: 675-682.
13. US Department of Health, and Human Services. Sequences of proteins of immunological interest, 1991. Report 91-3242. Bethesda, MD: US.
14. European Medicines Agency. Herceptin: EPAR-Scientific Discussion. 2005. London, UK.
15. Deen WM, Lazzara MJ, and Myers BD (2001). Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281: F579-F596.
16. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. (2013). Level of HER2 gene amplification predicts response, and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31: 4445-4452.
17. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney, DW Jr, et al. (2003). Structure of the extracellular region of HER2 alone, and in complex with the Herceptin Fab. Nature 421: 756-760.
18. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al. (2004). Endocytosis, and sorting of ErbB2, and the site of action of cancer therapeutics trastuzumab, and geldanamycin. Mol Biol Cell 15: 5268-5282.
19. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, and Baselga J (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal, and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
20. Yuan CX, Lasut AL, Wynn R, Neff NT, Hollis GF, Ramaker ML, et al. (2003). Purification of Her-2 extracellular domain, and identification of its cleavage site. Protein Expr Purif 29: 217-222.
21. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. (2002). Targeting ligand-Activated ErbB2 signaling inhibits breast, and prostate tumor growth. Cancer Cell 2: 127-137.
22. Diermeier-Daucher S, Hasmann M, and Brockhoff G (2008). Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci 1130: 280-286.
23. Sunada H, Magun BE, Mendelsohn J, and MacLeod CL (1986). Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825-3829.
24. Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, et al. (2012). Nonagonistic bivalent antibodies that promote c-MET degradation, and inhibit tumor growth, and others specific for tumor related c-MET. PLoS One 7: e34658.
25. Ren XR, Wei J, Lei G, Wang J, Lu J, Xia W, et al. (2012). Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization, and degradation in tumor cells. Breast Cancer Res 14: R89.
26. Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, et al. (2005). Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling, and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4: 1214-1221.
27. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. (2010). Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588-597.
28. Hommelgaard AM, Lerdrup M, and van Deurs B (2004). Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15: 1557-1567.
29. Shen F, Lin Q, Childress C, and Yang W (2008). Identification of the domain in ErbB2 that restricts ligand-induced degradation. Cell Signal 20: 779-786.
30. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, and Sela M (2009). Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106: 3294-3299.
31. Boersma YL, Chao G, Steiner D, Wittrup KD, and Plückthun A (2011). Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation, and receptor recycling. J Biol Chem 286: 41273-41285.
32. Doores KJ, Fulton Z, Huber M, Wilson IA, and Burton DR (2010). Antibody 2G12 recognizes di-mannose equivalently in domain-, and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84: 10690-10699.
33. Klapper LN, Waterman H, Sela M, and Yarden Y (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl, and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388.
34. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, et al. (2010). ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in nodenegative breast cancer. Clin Cancer Res 16: 451-460.
35. Weinstein IB, and Joe A (2008). Oncogene addiction. Cancer Res 68: 3077-80; discussion 3080.
36. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, et al. (2004). Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I, and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108: 71-77.
37. Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, et al. (2014). Integrative molecular, and functional profiling of ERBB2-Amplified breast cancers identifies new genetic dependencies. Oncogene 33: 619-631.
38. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.; ToGA Trial Investigators. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
39. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebocontrolled, phase 3 study. Lancet Oncol 14: 461-471.
40. Clynes RA, Towers TL, Presta LG, and Ravetch JV (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
41. Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. (2014). Dual targeting of HER2-positive cancer with trastuzumab emtansine, and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20: 456-468.
42. Shusta EV, Holler PD, Kieke MC, Kranz DM, and Wittrup KD (2000). Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 18: 754-759.
43. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, and Wittrup KD (2006). Isolating, and engineering human antibodies using yeast surface display. Nat Protoc 1: 755-768.